Role of Uralyt-U in Patients With Hyperuricemia

Last updated: April 16, 2020
Sponsor: Ai Peng
Overall Status: Active - Recruiting

Phase

N/A

Condition

Kidney Stones

Gout (Hyperuricemia)

Treatment

N/A

Clinical Study ID

NCT04352153
Uralyt-U
  • Ages 18-70
  • All Genders

Study Summary

The purpose of the study is to provide a more direct and objective basis for the widespread use of potassium sodium hydrogen citrate granules in the treatment of uric acid stones.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18-70 years old, male, outpatient or inpatient;

  • Acidic urinary stones

  • Serum uric acid value ≥480 µmol / L;

  • Other concomitant diseases (such as hypertension, hyperlipidemia, diabetes, etc.) arein a stable condition, and the dosage of other diseases is not changed during thetest.

  • eGFR≥30ml / min;

Exclusion

Exclusion Criteria:

  • Pregnant or lactating women;

  • Patients with acute or chronic renal failure (eGFR <30ml / min);

  • Patients with severe liver dysfunction (ALT, AST≥70 IU);

  • In patients with uncontrolled hypertension, systolic blood pressure ≥160 and / ordiastolic blood pressure ≥110mmHg;

  • In uncontrolled diabetic patients, fasting blood glucose is> 10mmol / L, and / orglycated hemoglobin is ≥9%;

  • Patients that are taking atorvastatin, losartan, amlodipine, fenofibrate,pyrazinamide, tincture diuretics, thiazide diuretics, glucocorticoids,immunosuppressive agents and other drugs that affect uric acid excretion Drugs, thosetaking aspirin at a dose of> 325mg / day;

  • Cancer patients

Study Design

Total Participants: 102
Study Start date:
April 01, 2020
Estimated Completion Date:
October 31, 2020

Study Description

Hyperuricemia (HUA) is a common systemic metabolic disease. Its incidence is increasing year by year and more young people suffer from hyperuricemia. HUA can not only cause the onset of gouty arthritis, and then affect joint function, and even cause joint deformities. It can also cause damage to multiple organs such as the heart, brain, and kidney through multiple channels. Chronic kidney disease (CKD) refers to chronic kidney structural and dysfunction caused by various reasons. HUA is an independent risk factor that accelerates the progress of CKD. Studies have shown that lowering uric acid is another key treatment to delay the progress of CKD. A large number of studies have shown that the formation of uric acid crystals is the main mechanism of inducing renal injury.

In 2017, the "Multidisciplinary Expert Consensus for the Diagnosis and Treatment of Hyperuricemia-Related Diseases in China" recommended that patients with hyperuricemia receiving uric acid lowering drugs, especially those treated with uric acid excretion drugs and patients with uric acid nephrolithiasis, recommended that the pH of urine be adjusted during pH6.2 ~ 6.9 to increase the solubility of uric acid in urine. It is recommended to use sodium bicarbonate or potassium sodium citrate drugs to alkalinize urine, but it is not clear if there is any difference in the kinetic parameters of urine alkalinity, compliance rate of alkalinized urine and safety between sodium bicarbonate and potassium sodium citrate. No "head-to-head" clinical publications have been reported. This clinical trial was designed to evaluate the rate of alkalinization of urine, the therapeutic effect of renal lithiasis and adverse reactions between the sodium bicarbonate and potassium sodium hydrogen citrate granules in healthy people and patients with hyperuricemia and renal calculi (uric acid). This study provides a more direct and objective basis for the widespread use of potassium sodium hydrogen citrate granules in the treatment of uric acid stones.

Connect with a study center

  • Department of Nephrolgoy, Shanghai 10th People's Hospital

    Shanghai, Shanghai 200072
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.